NCT01473563已完成2 期
Home Delivery of Pemetrexed as Maintenance Treatment in Patients Who Have Not Progressed After Induction Therapy for Advanced Nonsquamous Nonsmall Cell Lung Cancer: A Feasibility Study
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 52
- 试验地点
- 1
- 主要终点
- Percentage of Participants Who Adhered to Treatment Administration at Home
研究概览
简要总结
The main purpose for this study is to answer the following research questions:
- Can pemetrexed be administered safely at the participant's home, using the same treatment procedure as in a hospital setting?
- Will the participant be satisfied with home care?
- How might this impact the participant's quality of life?
- What are the required medical resources needed to give pemetrexed in a home setting?
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Have a histological or cytological diagnosis of NSCLC defined as nonsquamous cell histology. Squamous cell and/or small cell histology is not permitted. Mixed NSCLC tumors will be categorized by the predominant cell type. NSCLC tumors that are not otherwise specified with regard to histology or cannot be subclassified as squamous, adenocarcinoma, or large cell histology will be categorized as nonsquamous
- •Have Stage IIIB (not amenable to curative treatment) or Stage IV NSCLC prior to induction therapy as defined by the American Joint Committee on Cancer (AJCC) Staging Criteria for Lung Cancer
- •Have completed 4 induction cycles of platinum-based doublet therapy (type at the discretion of the physician) for treatment of their advanced disease.
- •Have not progressed after 4 cycles of induction therapy. Documented radiographic evidence of a tumor response must occur at the end of Cycle 4 of induction therapy within 3 weeks before receiving the first cycle of study drug [see Response Evaluation Criteria in Solid Tumors (RECIST), version (v) 1.1]
- •Receive on-study treatment no earlier than 21 days and no later than 42 days from Cycle 4 Day 1 of induction therapy
- •Have a Performance Status (PS) of 0 or 1 on the Eastern Cooperative Oncology Group (ECOG) scale
- •Meet the following guidelines if the participant has received prior radiation therapy:
- •Previous radiation therapy is allowed to <25% of the bone marrow, but should have been limited and must not have included whole pelvis radiation
- •Participants must have recovered from the toxic effects of the treatment prior to study enrollment (except for alopecia)
- •Participants who received palliative chest (in other words, thoracic skeleton including dorsal spine) or palliative extrathoracic radiotherapy to preexisting lesions are allowed to be enrolled in this trial
- •Have adequate organ function, including:
- •Adequate bone marrow reserve: absolute neutrophil count (ANC) (segmented and bands) >=1.5x109/Liter (L), platelets >=100x109/L, and hemoglobin >=9 grams per deciliter (g/dL)
- •Hepatic: bilirubin <=1.5 x upper limit of normal (ULN) and alkaline phosphatase (ALP), aspartate aminotransferase (AST), and alanine aminotransferase (ALT) <=3.0 x ULN (ALP, AST, and ALT <=5.0 x ULN are acceptable if the liver has tumor involvement
- •Renal: calculated creatinine clearance (CrCl) >=45 milliliters per minute (mL/min) based on the original weight-based Cockcroft and Gault formula
- •Are willing to comply with the following contraceptive criteria:
- •Females must be surgically sterile, postmenopausal or must have a negative serum or urine pregnancy test within 7 days prior to the first dose of study drug
- •Males and females with reproductive potential: Must agree to use a reliable method of birth control during the study and for 6 months following the last dose of study drug
- •Have an estimated life expectancy of at least 12 weeks
- •Have given written informed consent/assent prior to any study-specific procedures
- •Are willing to comply with home delivery administration and have family or close environment support willing to comply with home delivery administration
排除标准
- •Are currently enrolled in, or discontinued within the last 30 days from, a clinical trial involving an investigational product or no approved use of a drug or device (other than pemetrexed used in this study), or concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study
- •Have previously completed or withdrawn from this study
- •Have a serious concomitant systemic disorder (for example, active infection including human immunodeficiency virus)
- •Have a serious cardiac condition, such as myocardial infarction within 6 months, angina, or heart disease, as defined by the New York Heart Association Class III or IV
- •Have symptomatic central nervous system (CNS) malignancy or metastasis (screening not required). Participants with treated CNS metastases are eligible for this study if they are not currently receiving corticosteroids and/or anticonvulsants for at least 1 week before starting study treatment and their disease is asymptomatic and radiographically stable
- •Are receiving concurrent administration of any other antitumor therapy
- •Have a second primary malignancy that in the judgment of the investigator and sponsor may affect the interpretation of results
- •Are unable to interrupt aspirin or other nonsteroidal anti-inflammatory agents, other than aspirin dose ≤1.3 grams per day, for a 5-day period (8-day period for long-acting agents, such as piroxicam)
- •Are unable or unwilling to take folic acid or vitamin B12 supplementation
- •Are unable or unwilling to take corticosteroids
- •Are pregnant or lactating
- •Have received a recent (within 30 days of enrollment) or are receiving concurrent yellow fever vaccination
研究组 & 干预措施
Pemetrexed
Experimental
500 milligrams per square meter (mg/m^2) pemetrexed administered intravenously over approximately 10 minutes on Day 1 of a 21-day cycle. Maintenance therapy administered until disease progression or the participant is discontinued for any other reason. The first dose of maintenance therapy will be administered at the hospital; thereafter, therapy will be administered in the home setting by qualified oncology homecare nurses.
干预措施: Pemetrexed (Drug)
结局指标
主要结局
Percentage of Participants Who Adhered to Treatment Administration at Home
时间窗: Cycle 1, Day 1 through Cycle 19, Day 1 and Cycle 19, Day 1 (21 days/cycle)
Participants were considered adherent from the time of the first dose in Cycle 1 (hospital administration) until either the last day of the cycle when the participant reverted to pemetrexed hospital administration or the last day of the cycle when the participant discontinued study treatment or the study for reasons related to the home setting. The percentage of participants who adhered to treatment administration at home was estimated by a Kaplan-Meier survival analyses approach. Participants who died or discontinued the study and treatment without reverting to hospital administration were censored at the time of discontinuation.
次要结局
- Change From Baseline in the European Quality of Life Instrument (EQ-5D) Visual Analogue Scale (VAS)(Baseline, Day 1 of Cycles 2 and 4 (21 days/cycle) and 30 days post treatment discontinuation)
- Resource Utilization: Number of Participants With an Unplanned Use of Healthcare Resources(Cycle 1, Day 1 through last day of cycle when participant reverted to hospital administration or discontinued (up to Cycle 19, 21 days/cycle))
- Resource Utilization: Duration of Health Care Visits(Cycle 2, Day 1 through last day of cycle when participant reverted to hospital administration or discontinued (up to Cycle 4, 21 days/cycle))
- Change From Baseline in the EQ-5D Index Score(Baseline, Day 1 of Cycles 2 and 4 (21 days/cycle) and 30 days post treatment discontinuation)
- Participant Satisfaction: Regarding the Study Nurse(The first evaluation completed at either Cycle 4, Day 1 (21 days/cycle) or 30 days post treatment discontinuation)
- Time to Treatment Failure (TTF)(Cycle 1, Day 1 to first event (up to Cycle 19, 21 days/cycle))
- Resource Utilization: Distances Traveled(Cycle 1, Day 1 through last day of cycle when participant reverted to hospital administration or discontinued (up to Cycle 4, 21 days/cycle))
- Overall Survival (OS) at 6 Months(Cycle 1, Day 1 to the date of death from any cause (up to Month 6))
- Maximum Improvement Over Baseline in Individual Lung Cancer Symptoms Scale (LCSS) Item Scores(Baseline, Day 1 of each cycle (up to Cycle 19, 21 days/cycle), and 30 days post treatment discontinuation)
- Participant Satisfaction: Chemotherapy at Hospital(The first evaluation completed at either Cycle 4, Day 1 (21 days/cycle) or 30 days post treatment discontinuation)
- Resource Utilization: Unplanned Health Care Visits, Consultations, and Diagnostic Services(Cycle 1, Day 1 through last day of cycle when participant reverted to hospital administration or discontinued (up to Cycle 19, 21 days/cycle))
- Participant Satisfaction: Chemotherapy at Home(The first evaluation completed at either Cycle 4, Day 1 (21 days/cycle) or 30 days post treatment discontinuation)
- Participant Satisfaction: Preferences Regarding Home and/or Hospital Treatment(The first evaluation completed at either Cycle 4, Day 1 (21 days/cycle) or 30 days post treatment discontinuation)
- Physician Satisfaction: Distant Management of Participant(30 days post treatment discontinuation)
研究者
研究点 (1)
Loading locations...
相似试验
进行中（未招募）
不适用
Brighter Bites & University of Texas Physicians Produce Rx Extension: Evaluating the Effectiveness of a Prospective Clinical Nutrition Study With Produce PrescriptionsObesity, ChildhoodNCT06390397The University of Texas Health Science Center, Houston150
已完成
不适用
Brighter Bites & UT Physicians Produce Rx ProgramObesity, ChildhoodNCT05556070The University of Texas Health Science Center, Houston150
已完成
1 期
Home Care Medication Management Program for the Frail ElderlyChronic IllnessCognitive ImpairmentNCT01321853Arizona State University414
已完成
不适用
Domiciliary Diagnosis and Follow up in Obstructive Apnoea SyndromeObstructive Sleep ApneaNCT01001858Hospital Universitario San Juan de Alicante66
已完成
不适用
Homing in on Health: Study of a Home Delivered Chronic Disease Self Management ProgramArthritisCOPDDiabetes MellitusCongestive Heart FailureDepressionNCT00263939Agency for Healthcare Research and Quality (AHRQ)415